# Tofacitinib in Depression (TIDE)

> **NCT04141904** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Oxford** · enrollment: 2 (actual)

## Conditions studied

- Depression
- Inflammation

## Interventions

- **DRUG:** Tofacitinib 5 MG [Xeljanz]
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04141904
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-10
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Covid-19 pandemic
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141904, "Tofacitinib in Depression (TIDE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04141904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*